Temozolomide wafer - AccurexaAlternative Names: ACX-31 - Accurexa; ACX-31 wafer - Accurexa
Latest Information Update: 16 Jan 2017
At a glance
- Originator Accelerating Combination Therapies
- Developer Accelerating Combination Therapies; Accurexa; DelMar Pharmaceuticals
- Class 2 ring heterocyclic compounds; Amides; Epoxy compounds; Ethylene glycols; Imidazoles; Small molecules; Triazenes
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Brain cancer
- Research Solid tumours